Terms: = Lung cancer AND KMT2C, ENSG00000055609, MLL3, 58508
33 results:
1. Complex Genomic Rearrangement Patterns in Malignant Pleural Mesothelioma due to Environmental Asbestos Exposure.
Tuncel T; Ak G; Güneş HV; Metintaş M
J Environ Pathol Toxicol Oncol; 2024; 43(2):13-27. PubMed ID: 38505910
[TBL] [Abstract] [Full Text] [Related]
2. CRISPR/Cas9 model of prostate cancer identifies kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression.
Cai H; Zhang B; Ahrenfeldt J; Joseph JV; Riedel M; Gao Z; Thomsen SK; Christensen DS; Bak RO; Hager H; Vendelbo MH; Gao X; Birkbak N; Thomsen MK
Nat Commun; 2024 Mar; 15(1):2088. PubMed ID: 38453924
[TBL] [Abstract] [Full Text] [Related]
3. Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma.
de Miguel-Perez D; Pickering EM; Malapelle U; Grier W; Pepe F; Pisapia P; Russo G; Pinto JA; Russo A; Troncone G; Culligan MJ; Scilla KA; Mehra R; Mohindra P; Arrieta O; Cardona AF; Del Re M; Sachdeva A; Hirsch FR; Wolf A; Friedberg JS; Rolfo C
Eur J Cancer; 2024 Jan; 196():113457. PubMed ID: 38008032
[TBL] [Abstract] [Full Text] [Related]
4. LncRNA MIR31HG fosters stemness malignant features of non-small cell lung cancer via H3K4me1- and H3K27Ace-mediated GLI2 expression.
Chen W; Wang F; Yu X; Qi J; Dong H; Cui B; Zhang Q; Wu Y; An J; Ni N; Liu C; Han Y; Zhang S; Schmitt CA; Deng J; Yu Y; Du J
Oncogene; 2024 May; 43(18):1328-1340. PubMed ID: 37950038
[TBL] [Abstract] [Full Text] [Related]
5. Deciphering Brain Metastasis Stem Cell Properties From Colorectal cancer Highlights Specific Stemness Signature and Shared Molecular Features.
Desette A; Guichet PO; Emambux S; Masliantsev K; Cortes U; Ndiaye B; Milin S; George S; Faigner M; Tisserand J; Gaillard A; Brot S; Wager M; Tougeron D; Karayan-Tapon L
Cell Mol Gastroenterol Hepatol; 2023; 16(5):757-782. PubMed ID: 37482243
[TBL] [Abstract] [Full Text] [Related]
6. Genomic characteristics and prognosis of lung cancer patients with MSI-H: A cohort study.
Tian J; Wang H; Lu C; Liu L; Zhang X; Xie Y; Li R; Lv X; Fu D; Zhang L; Fang X; Wang X; Hu J; Liu X; Huang X; Zhao Q; Luo N; Tang H; Zhong Z; He Y; Li L
Lung Cancer; 2023 Jul; 181():107255. PubMed ID: 37244039
[TBL] [Abstract] [Full Text] [Related]
7. Frequently mutated genes in predicting the relapse of stage I lung adenocarcinoma.
Rao W; Yang L; Dai N; Zhang L; Liu J; Yang B; Li M; Shan J; Wang Q; Wang D
Clin Transl Oncol; 2023 Jun; 25(6):1767-1778. PubMed ID: 36739576
[TBL] [Abstract] [Full Text] [Related]
8. Genomic analyses of high-grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities.
Mahdi H; Joehlin-Price A; Elishaev E; Dowlati A; Abbas A
Mol Oncol; 2021 Dec; 15(12):3545-3558. PubMed ID: 34245124
[TBL] [Abstract] [Full Text] [Related]
9. Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report.
Liu Q; Wu L; Zhang S
Tumori; 2021 Dec; 107(6):NP5-NP10. PubMed ID: 33896242
[TBL] [Abstract] [Full Text] [Related]
10. Recruitment of kmt2c/mll3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in cancer.
Chang A; Liu L; Ashby JM; Wu D; Chen Y; O'Neill SS; Huang S; Wang J; Wang G; Cheng D; Tan X; Petty WJ; Pasche BC; Xiang R; Zhang W; Sun P
Cancer Res; 2021 Jun; 81(12):3358-3373. PubMed ID: 33853832
[TBL] [Abstract] [Full Text] [Related]
11. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract] [Full Text] [Related]
12. Targeted next-generation sequencing for cancer-associated gene mutation and copy number detection in 206 patients with non-small-cell lung cancer.
Zheng S; Wang X; Fu Y; Li B; Xu J; Wang H; Huang Z; Xu H; Qiu Y; Shi Y; Li K
Bioengineered; 2021 Dec; 12(1):791-802. PubMed ID: 33629637
[TBL] [Abstract] [Full Text] [Related]
13. Mutation profile of non-small cell lung cancer revealed by next generation sequencing.
Chang YS; Tu SJ; Chen YC; Liu TY; Lee YT; Yen JC; Fang HY; Chang JG
Respir Res; 2021 Jan; 22(1):3. PubMed ID: 33407425
[TBL] [Abstract] [Full Text] [Related]
14. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
[No Abstract] [Full Text] [Related]
15. Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Shang Y; Li X; Liu W; Shi X; Yuan S; Huo R; Fang G; Han X; Zhang J; Wang K; Dou Z; Zhang Y; Zang A; Zhang L
Sci Rep; 2020 Nov; 10(1):20243. PubMed ID: 33219256
[TBL] [Abstract] [Full Text] [Related]
16. Association of clinico-genomic characteristics with tumor mutational burden in small cell lung cancer patients.
Kachroo S; Shao C; Desai K; He J; Jin F; Sen S
Future Oncol; 2021 Feb; 17(4):423-433. PubMed ID: 33198513
[No Abstract] [Full Text] [Related]
17. kmt2c promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
Mastoraki S; Balgkouranidou I; Tsaroucha E; Klinakis A; Georgoulias V; Lianidou E
Mol Oncol; 2021 Sep; 15(9):2412-2422. PubMed ID: 33159839
[TBL] [Abstract] [Full Text] [Related]
18. H3K4 Methylation Status and Lysine Specific Methyltransferase kmt2c Expression Correlate with Prognosis in lung Adenocarcinoma.
Bosgana P; Nikou S; Dimitrakopoulos FI; Logotheti S; Tzelepi V; Kalophonos C; Bravou V; Kourea E; Sampsonas F; Zolota V
Curr Mol Pharmacol; 2021; 14(6):1028-1036. PubMed ID: 32867667
[TBL] [Abstract] [Full Text] [Related]
19. Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study.
Bai X; Wu DH; Ma SC; Wang J; Tang XR; Kang S; Fu QJ; Cao CH; Luo HS; Chen YH; Zhu HB; Yan HH; Wu YL; Dong ZY
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606052
[TBL] [Abstract] [Full Text] [Related]
20. Procarcinogen Activation and Mutational Signatures Model the Initiation of Carcinogenesis in Human Urothelial Tissues In Vitro.
Baker SC; Mason AS; Southgate J
Eur Urol; 2020 Aug; 78(2):143-147. PubMed ID: 32349929
[TBL] [Abstract] [Full Text] [Related]
[Next]
